

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number  
**WO 01/02017 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 47/48**

(21) International Application Number: **PCT/EP00/06009**

(22) International Filing Date: **28 June 2000 (28.06.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:

60/142,243	2 July 1999 (02.07.1999)	US
60/147,452	5 August 1999 (05.08.1999)	US
60/151,454	30 August 1999 (30.08.1999)	US

(71) Applicant: **F. HOFFMANN-LA ROCHE AG [CH/CH];**  
124 Grenzacherstrasse, CH-4070 Basle (CH).

(72) Inventors: **BURG, Josef;** An der Bärenmühle 1, D-82362 Weilheim (DE). **HILGER, Bernd;** 21 Am Katzenbuckel, D-82377 Penzberg (DE). **JOSEL, Hans-Peter;** Prälatenweg 7, D-82362 Weilheim (DE).

(74) Agent: **WITTE, Hubert;** Grenzacherstrasse 124, CH-4070 Basle (CH).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ERYTHROPOIETIN DERIVATIVES**

(57) Abstract: Erythropoietin glycoprotein conjugates are disclosed, said conjugates comprise an erythropoietin glycoprotein having at least one free amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the primary structure of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or by the rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to form one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the glycoprotein via a linker of the formula -C(O)-X-S-Y- with the C(O) of the linker forming an amide bond with one of said amino groups, wherein X and Y are as defined in the description and claims, the average molecular weight of each poly(ethylene glycol) moiety is from about 20 kilodaltons to about 40 kilodaltons, and the molecular weight of the conjugate is from about 51 kilodaltons to about 175 kilodaltons.

WO 01/02017 A2

Erythropoietin Derivatives

5

## BACKGROUND OF THE INVENTION

Erythropoiesis is the production of red blood cells which occurs to offset cell destruction. Erythropoiesis is a controlled physiological mechanism that enables sufficient red blood cells to be available for proper tissue oxygenation. Naturally occurring human erythropoietin (hEPO) is a glycoprotein containing 165 amino acids that is produced in the kidney and is the humoral plasma factor which stimulates red blood cell production (Carnot, P and Deflandre, C (1906) C.R. Acad. Sci. 143: 432; Erslev, AJ (1953 Blood 8: 349; Reissmann, KR (1950) Blood 5: 372; Jacobson, LO, Goldwasser, E, Freid, W and Plzak, LF (1957) Nature 179: 6331-4). Human EPO stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. Human EPO exerts its biological activity by binding to receptors on erythroid precursors (Krantz, BS (1991) Blood 77: 419). Naturally occurring human erythropoietin is an acidic glycoprotein present in low concentrations in plasma to stimulate replacement of red blood cells which are lost through ageing.

Erythropoietin has been manufactured biosynthetically using recombinant DNA technology (Egrie, JC, Strickland, TW, Lane, J et al. (1986) Immunobiol. 72: 213-224) and is the product of a cloned human EPO gene inserted into and expressed in the ovarian tissue cells of the chinese hamster (CHO cells). Naturally occurring human EPO is first


translated to a 166 aa containing polypeptide chain with arginine 166. In a postranslational modification arginine 166 is cleaved by a carboxypeptidase. The primary structure of human EPO (165 aa) is illustrated in Figure 1. The primary structure of human EPO (166 aa) is illustrated in Figure 2. There are two disulfide bridges between Cys<sup>7</sup>-Cys<sup>161</sup> and Cys<sup>29</sup>-Cys<sup>33</sup>. The molecular weight of the polypeptide chain of human EPO without the sugar moieties is 18,236 Da. In the intact EPO molecule, approximately 40% of the molecular weight is accounted for by the carbohydrate groups (Sasaki, H, Bothner, B, Dell, A and Fukuda, M (1987) J. Biol. Chem. 262: 12059).

Because erythropoietin is essential in red blood cell formation, the hormone is useful in the treatment of blood disorders characterized by low or defective red blood cell production. Clinically, EPO is used in the treatment of for example anemia in chronic renal failure patients (CRF) (Eschbach, JW, Egri, JC, Downing, MR et al. (1987) NEJM 316: 73-78; Eschbach, JW, Abdulhadi, MH, Browne, JK et al. (1989) Ann. Intern. Med. 111: 992; Egrie, JC, Eschbach, JW, McGuire, T, Adamson, JW (1988) Kidney Intl. 33: 262; Lim, VS, Degowin, RL, Zavala, D et al. (1989) Ann. Intern. Med. 110: 108-114) and in AIDS and cancer patients undergoing chemotherapy (Danna, RP, Rudnick, SA, Abels, RI In: MB, Garnick, ed. Erythropoietin in Clinical Applications-An International Perspective. New York, NY: Marcel Dekker;1990: p. 301-324). However, the bioavailability of currently available protein therapeutics such as EPO is limited by their short plasma half-life and susceptibility to protease degradation. These shortcomings prevent them from attaining maximum clinical potency.

## SUMMARY OF THE INVENTION

Accordingly, the present invention is a new class of PEG derivatives of EPO. The physiologically active PEG-EPO conjugates of this invention comprise an erythropoietin glycoprotein having at least one free amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the primary structure of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites; said glycoprotein being covalently linked to from one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the glycoprotein via a linker of the formula -C(O)-X-S-Y- with the C(O) of the linker forming an amide bond with one of said amino groups, X is -(CH<sub>2</sub>)<sub>k</sub>- or -CH<sub>2</sub>(O-CH<sub>2</sub>-CH<sub>2</sub>)<sub>k</sub>-, k is from 1 to 10, Y is

- 3 -



the average molecular weight of each poly(ethylene glycol) moiety is from about 20 kilodaltons to about 40 kilodaltons, and the molecular weight of the conjugate is from about 51 kilodaltons to about 175 kilodaltons. This invention further provides

5 compositions containing conjugates described herein in which the percentage of conjugates in the composition in which  $n$  is 1 is at least ninety percent.

Compared to unmodified EPO (i.e., EPO without a PEG attached) and conventional PEG-EPO conjugates, the present conjugates have an increased circulating half-life and plasma residence time, decreased clearance, and increased clinical activity *in vivo*. The

10 conjugates of this invention have the same uses as EPO. In particular, the conjugates of this invention are useful to treat patients by stimulating the division and differentiation of committed erythroid progenitors in the bone marrow in the same way EPO is used to treat patients.

The present invention also includes a method for the treatment of anemia in a human.

15 The present invention also includes a method for preparing the erythropoietin glycoprotein products which comprises covalently reacting an  $\epsilon$ -amino group of a lysine amino acid of an erythropoietin protein with a bi-functional reagent to form an intermediate with an amide linkage. The bi-functional reagent contains a reactive group and a protected thiol group. The amide-linked intermediate is then covalently reacted

20 with an activated polyethylene glycol derivative to form the erythropoietin glycoprotein product of the present invention.

## DESCRIPTION OF THE DRAWINGS

Figure 1: Primary structure of human EPO (165 amino acids).

25 Figure 2: Primary structure of human EPO (166 amino acids)

Figure 3: In vivo activity of pegylated EPO determined by normocythaemic mouse assay.

## DETAILED DESCRIPTION OF THE INVENTION

### Definitions

5       The following terms shall have the definitions set out below:

      The term "erythropoietin protein", "erythropoietin", "EPO", or "erythropoietin glycoprotein" refers to a glycoprotein having the sequence shown in Figure 1 (SEQ ID NO:1) or 2 (SEQ ID NO:2), or a protein or polypeptide substantially homologous thereto, whose biological properties relate to the stimulation of red blood cell production and the  
10   stimulation of the division and differentiation of committed erythroid progenitors in the bone marrow. As used herein the term EPO protein includes such proteins modified deliberately, as for example, by site directed mutagenesis or accidentally through mutations. These terms also include analogs having from 1 to 6 additional glycosylation sites, analogs having at least one additional amino acid at the carboxy terminal end of the  
15   protein wherein the additional amino acid(s) includes at least one glycosylation site, and analogs having an amino acid sequence which includes a rearrangement of at least one glycosylation site, such as for example the analogs disclosed in European Patent Publication No. 640 619. These terms include both natural and recombinantly produced human erythropoietin.

20       The term "substantially homologous" means that a particular subject sequence, for example, a mutant sequence, varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and subject sequences. For purposes of the present invention, sequences having greater than 95 percent homology, equivalent  
25   biological properties, and equivalent expression characteristics are considered substantially homologous. For purposes of determining homology, truncation of the mature sequence should be disregarded. Sequences having lesser degrees of homology, comparable bioactivity, and equivalent expression characteristics are considered substantial equivalents.

30       The term "fragment" of the EPO protein means any protein or polypeptide having the amino acid sequence of a portion or fragment of an EPO protein, and which has the biological activity of the EPO. Fragments include proteins or polypeptides produced by

proteolytic degradation of the EPO protein or produced by chemical synthesis by methods routine in the art. An EPO protein or fragment thereof is biologically active when administration of the protein or fragment to man results in the stimulation of red blood cell production and the stimulation of the division and differentiation of committed erythroid progenitors in the bone marrow. Determining such biological activity of the EPO protein can be carried out by conventional, well known tests utilized for such purposes on one or more species of mammals. An appropriate test which can be utilized to demonstrate such biological activity is described herein.

The term "therapeutically effective amount" is that amount of erythropoietin glycoprotein product necessary for the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells. The exact amount of erythropoietin glycoprotein product is a matter of preference subject to such factors as the exact type of condition being treated, the condition of the patient being treated, as well as the other ingredients in the composition. The pharmaceutical compositions containing the erythropoietin glycoprotein products may be formulated at a strength effective for administration by various means to a human patient experiencing blood disorders characterized by low or defective red blood cell production. Average therapeutically effective amounts of the erythropoietin glycoprotein product may vary and in particular should be based upon the recommendations and prescription of a qualified physician.

The present invention is directed to erythropoietin glycoprotein products having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells represented by Formula 1:



wherein X and Y are as defined above, m is from 450 to 900, n is from 1 to 3, R is lower alkyl and P is an erythropoietin glycoprotein less the amino group or amino groups which form an amide linkage with X. As set out in detail below, the preparation and purification of EPO are well known in the art. By EPO is meant the natural or recombinant protein, preferably human, as obtained from any conventional source such as tissues, protein synthesis, cell culture with natural or recombinant cells. Any protein having the activity of EPO, such as muteins or otherwise modified proteins, is encompassed. Recombinant EPO may be prepared via expression in CHO-, BHK- or HeLa cell lines, by recombinant DNA technology or by endogenous gene activation, i.e. the erythropoietin glycoprotein is expressed by endogenous gene activation. The preferred EPO species for the preparation of erythropoietin glycoprotein products are human EPO species. More preferably, the EPO

species is the human EPO having the amino acid sequence set out in Figure 1 (SEQ ID NO:1) or Figure 2 (SEQ ID NO:2), most preferably the human EPO having the amino acid sequence set out in Figure 1 (SEQ ID NO:1).

The human erythropoietin protein may also be modified to at least one additional site for glycosylation, e.g. 1 to 6 additional glycosylation sites, such as, but not limited to, the amino acid sequences as set out below. The notation below means that the sequence set forth in Figure 1 has been modified by substituting the native amino acid at the superscripted numbered position shown for the amino acid indicated to the left of the superscripted number.

- 10                   Asn<sup>30</sup>Thr<sup>32</sup> Figure 1;
- Asn<sup>51</sup>Thr<sup>53</sup> Figure 1;
- Asn<sup>57</sup>Thr<sup>59</sup> Figure 1;
- Asn<sup>69</sup> Figure 1;
- Asn<sup>69</sup>Thr<sup>71</sup> Figure 1;
- 15                   Ser<sup>68</sup>Asn<sup>69</sup>Thr<sup>71</sup> Figure 1;
- Val<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup> Figure 1;
- Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup> Figure 1;
- Ser<sup>87</sup>Asn<sup>88</sup>Gly<sup>89</sup>Thr<sup>90</sup> Figure 1;
- Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>Thr<sup>92</sup> Figure 1;
- 20                   Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>Ala<sup>162</sup> Figure 1;
- Asn<sup>69</sup>Thr<sup>71</sup>Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup> Figure 1;
- Asn<sup>30</sup>Thr<sup>32</sup>Val<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup> Figure 1;
- Asn<sup>89</sup>Ile<sup>90</sup>Thr<sup>91</sup> Figure 1;
- Ser<sup>87</sup>Asn<sup>89</sup>Ile<sup>90</sup>Thr<sup>91</sup> Figure 1;
- 25                   Asn<sup>136</sup>Thr<sup>138</sup> Figure 1;
- Asn<sup>138</sup>Thr<sup>140</sup> Figure 1;
- Thr<sup>125</sup> Figure 1; and
- Pro<sup>124</sup>Thr<sup>125</sup> Figure 1.

- 30                   The human erythropoietin protein may also be an analog having at least one additional amino acid at the carboxy terminal end of the glycoprotein, wherein the additional amino acid includes at least one glycosylation site, i.e. the glycoprotein has a sequence comprising the sequence of human erythropoietin and a second sequence at the carboxy terminus of the human erythropoietin sequence, wherein the second sequence
- 35                   contains at least one glycosylation site.

The additional amino acid may comprise a peptide fragment derived from the carboxy terminal end of human chorionic gonadotropin. Preferably, the glycoprotein is an analog selected from the group consisting of (a) human erythropoietin having the amino acid sequence, Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu  
 5 Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln (SEQ ID NO:3), extending from the carboxy terminus; (b) the analog in (a) further comprising Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO; and (c) the analog in (a) further comprising Asn<sup>30</sup> Thr<sup>32</sup> Val<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO.


The human erythropoietin protein may also be an analog having an amino acid sequence which includes a rearrangement of at least one site for glycosylation. The  
 10 rearrangement may comprise a deletion of any of the N-linked carbohydrate sites in human erythropoietin and an addition of an N-linked carbohydrate site at position 88 of the amino acid sequence of human erythropoietin. Preferably, the glycoprotein is an analog selected from the group consisting of Gln<sup>24</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO; Gln<sup>38</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO; and Gln<sup>83</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO.

15 Erythropoietin analogs with additional glycosylation sites are disclosed in European Patent Publication No. 640 619, to Elliot, published March 1, 1995, the contents of which are incorporated herein by reference.

In Formula 1, R may be any lower alkyl, by which is meant a linear or branched alkyl group having from one to six carbon atoms such as methyl, ethyl, isopropyl, etc. A  
 20 preferred alkyl is methyl.


In Formula 1, X is  $-(CH_2)_k-$  or  $-CH_2(O-CH_2-CH_2)_k-$ , wherein k is from 1 to about 10. Preferably, k is from 1 to about 4, more preferably, k is 1 or 2. Most preferably, X is  $-(CH_2)-$ .

In Formula 1, Y is






Preferably Y is



5 Most preferably, Y is





In Formula 1, the number  $m$  is selected such that the resulting conjugate of Formula 1 has a physiological activity comparable to unmodified EPO, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified EPO.

10  $m$  represents the number of ethylene oxide residues in the PEG unit. A single PEG subunit of  $-(OCH_2CH_2)-$  has a molecular weight of about 44 daltons. Thus, the molecular weight of the conjugate (excluding the molecular weight of the EPO) depends on the number  $m$ . A molecular weight of "about" a certain number means that it is within a reasonable range of that number as determined by conventional analytical techniques.  $m$  is an integer  
15 ranging from about 450 to about 900 (corresponding to a molecular weight of from 20 to 40 kDa), preferably  $m$  is from about 550 to about 800 (about 24 to 35 kDa), and most preferably  $m$  is from about 650 to about 700 (about 29 to about 31 kDa).


In Formula 1, the number  $n$  is the number of  $\epsilon$ -amino groups of a lysine amino acid in an erythropoietin protein covalently bound to a PEG unit via an amide linkage. A  
20 conjugate of this invention may have one, two, or three PEG units per molecule of EPO.  $n$  is an integer ranging from 1 to 3, preferably  $n$  is 1 or 2, and more preferably  $n$  is 1.

Preferred erythropoietin glycoprotein products are represented by the formulae:





wherein P, R, X, m and n are as defined above.

Most preferred erythropoietin glycoprotein products are represented by the formula:




5 wherein P, R, X, M and n are as defined above.

Other preferred erythropoietin glycoprotein products are represented by the formulae:



wherein P and n are as defined above.

10 More preferred erythropoietin glycoprotein products are represented by the formula:



wherein P and n are as defined above.

Preferred compounds are those wherein X is  $-(CH_2)_k-$ , especially those wherein k is from 1 to 4, most preferably those, wherein X is  $-CH_2-$ .

5 The invention also relates to the above conjugates wherein m is an integer from 550 to 800, preferably m is an integer from 650 to 700.

Preferred compounds of the present invention are those wherein n is 1 and/or R is methyl.

10 In addition, the invention relates to the above compounds wherein the average molecular weight of each poly(ethylene glycol) moiety is from about 24 kilodaltons to about 35 kilodaltons, more preferably to about 30 kilodaltons.

Further, the present invention relates to compounds, wherein the glycoprotein is covalently linked to one or two lower-alkoxy capped poly(ethylene glycol) moieties, more preferably to one lower-alkoxy capped poly(ethylene glycol) moiety.

15 In a preferred embodiment, the poly(ethylene glycol) moieties are capped by methoxy.

In the most preferred embodiment; the invention relates to the above compounds wherein X is  $-CH_2-$ , m is an integer from 650 to 700, n is 1, R is methyl, and wherein the average molecular weight of each poly(ethylene glycol) moiety is about 30 kilodaltons.

20 In yet another embodiment, the invention is directed to a method for the treatment of anemia in a human which comprises administering to a human a therapeutically effective amount of an erythropoietin glycoprotein product represented by Formula 1.


In still another embodiment, the invention is directed to a method for preparing an erythropoietin glycoprotein product, having the *in vivo* biological activity of causing bone  
25 marrow cells to increase production of reticulocytes and red blood cells, which comprises the steps of:

(a) covalently reacting an  $\epsilon$ -amino group of a lysine amino acid of an erythropoietin protein represented by the formula,  $P-[NH_2]_n$ , with a bi-functional reagent represented by the formula,  $Z-CO-X-S-Q$ , to form an intermediate with an amide linkage represented by the formula:




wherein P is an erythropoietin protein less the amino group which forms an amide linkage; n is an integer ranging from 1 to 3; Z is a reactive group, e.g. a carboxylic-NHS ester; X is  $-(CH_2)_k-$  or  $-CH_2(O-CH_2-CH_2)_k-$ , wherein k is from 1 to about 10; and Q is a protecting group, like alkanoyl, e.g. acetyl.

10 (b) covalently reacting the intermediate with an amide linkage from step (a) with an activated polyethylene glycol derivative represented by the formula,  $W-[OCH_2CH_2]_m-OR$ , to form an erythropoietin glycoprotein product represented by the formula:



15 wherein W is a sulfhydryl reactive form of Y; m is an integer ranging from about 450 to about 900; R is lower alkyl; and Y is




In this embodiment, the bi-functional reagent is preferably N-succinimidyl-S-acetylthiopropionate or N-succinimidyl-S-acetylthioacetate, Z is preferably N-hydroxy-succinimide, and the activated polyethylene glycol derivative  $W-[OCH_2CH_2]_m-OR$  is preferably selected from the group consisting of iodo-acetyl-methoxy-PEG, methoxy-PEG-20 vinylsulfone, and methoxy-PEG-maleimide.

A further embodiment of the present invention refers to a composition comprising conjugates, each of said conjugates comprising an erythropoietin glycoprotein having at least one free amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the primary structure of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or by the rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to from one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the glycoprotein *via* a linker of the formula  $-C(O)-X-S-Y-$  with the C(O) of the linker forming an amide bond with one of said amino groups,

X is  $-(CH_2)_k-$  or  $-CH_2(O-CH_2-CH_2)_k-$ ,

k is from 1 to 10,

Y is



15

the average molecular weight of each poly(ethylene glycol) moiety is from about 20 kilodaltons to about 40 kilodaltons, and the molecular weight of the conjugate is from about 51 kilodaltons to about 175 kilodaltons; and the percentage of conjugates where n is 1 is at least ninety percent. Preferably the composition comprises conjugates as defined above wherein the percentage of conjugates where n is 1 is at least ninety percent, more preferably wherein the percentage of conjugates where n is 1 is at least ninety-two percent, and even more preferably wherein the percentage of conjugates where n is 1 is at least ninety-six percent, and most preferably wherein the percentage of conjugates where n is 1 is from ninety percent to ninety-six percent.

25

Further, the present invention refers to a pharmaceutical composition comprising a conjugate or a composition as defined above and a pharmaceutically acceptable excipient and to the use of a conjugate or a composition as defined above for the preparation of

medicaments for the treatment or prophylaxis of diseases correlated with anemia in chronic renal failure patients (CRF), AIDS and for the treatment of cancer patients undergoing chemotherapy. In addition, the invention refers to a method for the prophylactic and/or therapeutic treatment of disorders involving anemia in chronic renal failure patients (CRF), AIDS and cancer patients undergoing chemotherapy comprising the step of administering to a patient a composition as defined above.

The invention also relates to a process for the preparation of conjugates or composition as defined above which process comprises the covalent linking of thiol groups to an erythropoietin glycoprotein and coupling the resulting activated erythropoietin glycoprotein with a poly(ethylene glycol) (PEG) derivative. Further, the invention refers to conjugates and compositions as defined above whenever prepared by the processes described above and to conjugates and compositions as defined above for the treatment of diseases which are associated with anemia in chronic renal failure patients (CRF), AIDS and cancer patients undergoing chemotherapy.

#### Methods for Expressing EPO Proteins

Erythropoietin (EPO) is a human glycoprotein which stimulates the formation of erythrocytes. Its preparation and therapeutic application are described in detail for example in U.S. Patent Nos. 5,547,933 and 5,621,080, EP-B 0 148 605, Huang, S.L., Proc. Natl. Acad. Sci. USA (1984) 2708-2712, EP-B 0 205 564, EP-B 0 209 539 and EP-B 0 411 678 as well as Lai, P.H. et al., J. Biol. Chem. 261 (1986) 3116-3121, an Sasaki, H. et al., J. Biol. Chem. 262 (1987) 12059-12076. Erythropoietin for therapeutic use may be produced by recombinant means (EP-B 0 148 605, EP-B 0 209 539 and Egrie, J.C., Strickland, T.W., Lane, J. et al. (1986) Immunobiol. 72: 213-224). Expression of proteins, including EPO, by endogenous gene activation is well known in the art and is disclosed, for example in U.S. Patents Nos. 5,733,761, 5,641,670, and 5,733,746, and international patent publication Nos. WO 93/09222, WO 94/12650, WO 95/31560, WO 90/11354, WO 91/06667 and WO 91/09955, the contents of each of which are incorporated herein by reference.

Methods for the expression and preparation of erythropoietin in serum free medium are described for example in WO 96/35718, to Burg published 14 November 1996, and in European Patent Publication No. 513 738, to Koch published 12 June 1992.

## Methods for Purifying Human EPO Protein

In addition to the references mentioned above, it is known that a serum-free fermentation of recombinant CHO cells which contain an EPO gene can be carried out. Such methods are described for example in EP-A 0 513 738, EP-A 0 267 678 and in a  
5 general form by Kawamoto, T. et al., Analytical Biochem. 130 (1983) 445-453, EP-A 0 248 656, Kowar, J. and Franek, F., Methods in Enzymology 421 (1986) 277-292, Bavister, B., Expology 271 (1981) 45-51, EP-A 0 481 791, EP-A 0 307 247, EP-A 0 343 635, WO 88/00967.

In EP-A 0 267 678 an ion exchange chromatography on S-Sepharose, a preparative  
10 reverse phase HPLC on a C<sub>8</sub> column and a gel filtration chromatography are described for the purification of EPO produced in serum-free culture after dialysis. In this connection the gel filtration chromatography step can be replaced by ion exchange chromatography on S-Sepharose fast flow. It is also proposed that a dye chromatography on a Blue Trisacryl column be carried out before the ion exchange chromatography.

15 A process for the purification of recombinant EPO is described by Nobuo, I. et al., J. Biochem. 107 (1990) 352-359. In this process EPO is treated however with a solution of Tween<sup>®</sup> 20, phenylmethylsulfonyl fluoride, ethylmaleimide, pepstatin A, copper sulfate and oxamic acid prior to the purification steps.

Multiple references like WO 96/35718, to Burg published 14 November 1996,  
20 discloses a process for preparing erythropoietin in a serum free fermentation process (EPOsf). One method to manufacture EPO as starting material for the pegylation is explained exemplary in the following.


## Biological Assay for Determining Specific Activity of EPO and EPO Conjugates

25 The specific activity of EPO or EPO conjugates in accordance with this invention can be determined by various assays known in the art. The biological activity of the purified EPO proteins of this invention are such that administration of the EPO protein by injection to human patients results in bone marrow cells increasing production of reticulocytes and red blood cells compared to non-injected or control groups of subjects.  
30 The biological activity of the EPO proteins, or fragments thereof, obtained and purified in accordance with this invention can be tested by methods according to Pharm. Europa Spec. Issue Erythropoietin BRP Bio 1997(2).


Another biological assay for determining the activity of EPO protein, the normocythaemic mouse assay, is described in Example 4.

### Processes for the Preparation of Pegylated EPO

Processes for the preparation of erythropoietin glycoprotein products represented by Formula 1 comprise the covalent linking of thiol groups to EPO ("activation") and coupling the resulting activated EPO with a poly(ethylene glycol) (PEG) derivative. The first step for the preparation of pegylated EPO according to the present invention comprises covalent linking of thiol groups via  $\text{NH}_2$ -groups of EPO. This activation of EPO is performed with bi-functional reagents which carry a protected thiol group and an additional reactive group, such as active esters (e.g., a succinimidylester), anhydrides, esters of sulphonic acids, halogenides of carboxylic acids and sulphonic acids, respectively. The thiol group is protected by groups known in the art, e.g., acetyl groups. These bi-functional reagents are able to react with the  $\epsilon$ -amino groups of the lysine amino acids by forming an amide linkage. The first step of the reaction is set out below:



EPO, n and X are as defined above and Z is a reactive group known in the art, e.g. a N-hydroxy-succinimide (NHS) substituent of the formula




20


In a preferred embodiment the activation of the  $\epsilon$ -amino lysine groups is performed by reaction with bi-functional reagents having a succinimidyl moiety. The bi-functional reagents may carry different spacer species, e.g.  $-(\text{CH}_2)_k-$  or  $-\text{CH}_2-(\text{O}-\text{CH}_2-\text{CH}_2-)_k-$  moieties, wherein k is from 1 to about 10, preferably from 1 to about 4, and more preferably 1 or 2, and most preferably 1. Examples of these reagents are N-succinimidyl-S-acetylthiopropionate (SATP) and N-succinimidyl-S-acetylthioacetate (SATA)

25







Acetylthioalkyl-carboxylic-NHS-ester, like



SATP



SATA

2-(Acetylthio)-(ethoxy)<sub>k</sub>-acetic-acid-NHS-ester

with k as defined above.

The preparation of the bi-functional reagents is known in the art. Precursors of 2-(acetylthio)-(ethoxy)<sub>k</sub>-acetic-acid-NHS-esters are described in DE-3924705, while the derivatization to the acetylthio compound is described by March, J., Advanced Organic Chemistry, McGraw-Hill, 1977, 375-376. SATA is commercially available (Molecular Probes, Eugene, OR, USA and Pierce, Rockford, IL).


The number of thiol groups to be added to an EPO molecule can be selected by adjusting the reaction parameters, i.e., the protein (EPO) concentration and the protein/bi-functional reagent ratio. Preferably, the EPO is activated by covalently linking from 1 to 5 thiol groups per EPO molecule, more preferably from 1.5 to 3 thiol groups per EPO molecule. These ranges refer to the statistical distribution of the thiol group over the EPO protein population.

The reaction is carried out, for example, in an aqueous buffer solution, pH 6.5–8.0, e.g., in 10 mM potassium phosphate, 50 mM NaCl, pH 7.3. The bi-functional reagent may be added in DMSO. After completion of the reaction, preferably after 30 minutes, the reaction is stopped by addition of lysine. Excess bifunctional reagent may be separated by methods known in the art, e.g., by dialysis or column filtration. The average number of

thiol groups added to EPO can be determined by photometric methods described in, for example, Grasetti, D.R. and Murray, J.F. in *J. Appl. Biochem. Biotechnol.* 119, 41 – 49 (1967).


The above reaction is followed by covalent coupling of an activated polyethylene glycol (PEG) derivative. Suitable PEG derivatives are activated PEG molecules with an average molecular weight of from about 20 to about 40 kDa, more preferably from about 24 to about 35 kDa, and most preferably about 30 kDa.

Activated PEG derivatives are known in the art and are described in, for example, Morpurgo, M. et al. *J. Bioconj. Chem.* (1996) 7, page 363 ff for PEG-vinylsulfone. Linear chain and branched chain PEG species are suitable for the preparation of the compounds of Formula 1. Examples of reactive PEG reagents are iodo-acetyl-methoxy-PEG and methoxy-PEG-vinylsulfone:




The use of these iodo-activated substances is known in the art and described e.g. by Hermanson, G. T. in *Bioconjugate Techniques*, Academic Press, San Diego (1996) p. 147-148.

Most preferably, the PEG species are activated by maleimide using (alkoxy-PEG-maleimide), such as methoxy-PEG-maleimide (MW 30000; Shearwater Polymers, Inc.). The structure of alkoxy-PEG-maleimide is as follows:



with R and m are as defined above.

The most preferred derivative is



wherein R and m are as defined above.

The coupling reaction with alkoxy-PEG-maleimide takes place after *in situ* cleavage of the thiol protecting group in an aqueous buffer solution, e.g. 10 mM potassium phosphate, 50 mM NaCl, 2 mM EDTA, pH 6.2. The cleavage of the protecting group may be performed, for example, with hydroxylamine in DMSO at 25°C, pH 6.2 for about 90 minutes. For the PEG modification the molar ratio of activated EPO/alkoxy-PEG-maleimide should be from about 1:3 to about 1:6, and preferably 1:4. The reaction may be stopped by addition of cysteine and reaction of the remaining thiol (-SH) groups with N-methylmaleimide or other appropriate compounds capable of forming disulfide bonds. Because of the reaction of any remaining active thiol groups with a protecting group such as N-methylmaleimide or other suitable protecting group, the EPO glycoproteins in the conjugates of this invention may contain such protecting groups. Generally the procedure described herein will produce a mixture of molecules having varying numbers of thiols protected by different numbers of the protecting group, depending on the number of activated thiol groups on the glycoprotein that were not conjugated to PEG-maleimide.

Whereas N-methylmaleimide forms the same type of covalent bond when used to block the remaining thiol-groups on the pegylated protein, disulfide compounds will lead in an intermolecular sulfide/disulfide exchange reaction to a disulfide bridged coupling of the blocking reagent. Preferred blocking reagents for that type of blocking reaction are oxidized glutathione (GSSG), cysteine and cystamine. Whereas with cysteine no additional net charge is introduced into the pegylated protein, the use of the blocking reagents GSSG or cystamine results in an additional negative or positive charge.

The further purification of the compounds of Formula 1, including the separation of mono-, di- and tri-pegylated EPO species, may be done by methods known in the art, e.g., column chromatography.

## Pharmaceutical Compositions

The erythropoietin glycoprotein products prepared in accordance with this invention may be prepared in pharmaceutical compositions suitable for injection with a pharmaceutically acceptable carrier or vehicle by methods known in the art. For example, appropriate compositions have been described in WO97/09996, WO97/40850, WO98/58660, and WO99/07401. Among the preferred pharmaceutically acceptable carriers for formulating the products of the invention are human serum albumin, human plasma proteins, etc. The compounds of the present invention may be formulated in 10 mM sodium/potassium phosphate buffer at pH 7 containing a tonicity agent, e.g. 132 mM sodium chloride. Optionally the pharmaceutical composition may contain a preservative. The pharmaceutical composition may contain different amounts of erythropoietin, e.g. 10 – 1000 µg/ml, e.g. 50 µg or 400 µg.

## Treating Blood Disorders Characterized by Low or Defective Red Blood Cell Production

Administration of the erythropoietin glycoprotein products of the present invention results in red blood cell formation in humans. Therefore, administration of the erythropoietin glycoprotein products replenishes this EPO protein which is important in the production of red blood cells. The pharmaceutical compositions containing the erythropoietin glycoprotein products may be formulated at a strength effective for administration by various means to a human patient experiencing blood disorders characterized by low or defective red blood cell production, either alone or as part condition or disease. The pharmaceutical compositions may be administered by injection such as by subcutaneous or intravenous injection. Average quantities of the erythropoietin glycoprotein product may vary and in particular should be based upon the recommendations and prescription of a qualified physician. The exact amount of conjugate is a matter of preference subject to such factors as the exact type of condition being treated, the condition of the patient being treated, as well as the other ingredients in the composition. For example, 0.01 to 10 µg per kg body weight, preferably 0.1 to 1 µg per kg body weight, may be administered e.g. once weekly.

30

Throughout this application, various publications have been referenced. The disclosures in these publications are incorporated herein by reference in order to describe more fully the state of the art.

The present invention is further illustrated by the following examples which are presented for purposes of demonstrating, but not limiting, the preparation of the compounds and compositions of this invention.

The column is packed with 30 - 40 l of Butyl Toyopearl 650 C, regenerated with NaOH, washed with a Tris-base buffer and equilibrated with a Tris-base buffer containing isopropanol.

5 The Blue Sepharose eluate is adjusted to the concentration of isopropanol in the column equilibration buffer and loaded onto the column. Then the column is washed with equilibration buffer with increased isopropanol concentration. The product is eluted with elution buffer (Tris-base buffer with high isopropanol content) and collected in a single fraction in accordance with the master elution profile.

#### 10 c) Hydroxyapatite Ultrogel Chromatography

The Hydroxyapatite Ultrogel (Biosepra) consists of hydroxyapatite which is incorporated in an agarose matrix to improve the mechanical properties. EPO has a low affinity to hydroxyapatite and can therefore be eluted at lower phosphate concentrations than protein impurities.

15 The column is filled with 30 - 40 l of Hydroxyapatite Ultrogel and regenerated with a potassium phosphate/ calcium chloride buffer and NaOH followed by a Tris-base buffer. Then it is equilibrated with a Tris-base buffer containing a low amount of isopropanol and sodium chloride.

20 The EPO containing eluate of the Butyl Toyopearl chromatography is loaded onto the column. Subsequently the column is washed with equilibration buffer and a Tris-base buffer without isopropanol and sodium chloride. The product is eluted with a Tris-base buffer containing a low concentration of potassium phosphate and collected in a single fraction in accordance with the master elutiogram.

#### 25 d) Reversed Phase HPLC on Vydac C4

The RP-HPLC material Vydac C4 (Vydac) consists of silica gel particles, the surfaces of which carry C4-alkyl chains. The separation of EPO from the proteinaceous impurities is based on differences in the strength of hydrophobic interactions. Elution is performed with an acetonitrile gradient in diluted trifluoroacetic acid.

Preparative HPLC is performed using a stainless steel column (filled with 2.8 to 3.2 liter of Vydac C4 silicagel). The Hydroxyapatite Ultrogel eluate is acidified by adding trifluoro-acetic acid and loaded onto the Vydac C4 column. For washing and elution an acetonitrile gradient in diluted trifluoroacetic acid is used. Fractions are collected and immediately neutralized with phosphate buffer. The EPO fractions which are within the IPC limits are pooled.

#### e) DEAE Sepharose Chromatography

The DEAE Sepharose (Pharmacia) material consists of diethylaminoethyl (DEAE) - groups which are covalently bound to the surface of Sepharose beads. The binding of EPO to the DEAE groups is mediated by ionic interactions. Acetonitrile and trifluoroacetic acid pass through the column without being retained. After these substances have been washed off, trace impurities are removed by washing the column with acetate buffer at a low pH. Then the column is washed with neutral phosphate buffer and EPO is eluted with a buffer with increased ionic strength.

The column is packed with DEAE Sepharose fast flow. The column volume is adjusted to assure an EPO load in the range of 3 - 10 mg EPO/ml gel. The column is washed with water and equilibration buffer (sodium/ potassium phosphate). The pooled fractions of the HPLC eluate are loaded and the column is washed with equilibration buffer. Then the column is washed with washing buffer (sodium acetate buffer) followed by washing with equilibration buffer. Subsequently, EPO is eluted from the column with elution buffer (sodium chloride, sodium/ potassium phosphate) and collected in a single fraction in accordance with the master elution profile.

The eluate of the DEAE Sepharose column is adjusted to the specified conductivity. The resulting drug substance is sterile filtered into Teflon bottles and stored at -70 °C.

#### EXAMPLE 2: Covalent Linking of thiol groups to EPO

This example discloses the determination of reaction conditions for the covalent linking of thiol groups to EPO. To determine the conditions, different amounts of a reagent containing a blocked thiol group, here SATA or SATP (dissolved in DMSO at 10 mg/ml) were added to the EPO solution, here to 1 ml of 5 mg/ml EPO in 10 mM potassium phosphate, 50 mM NaCl, pH 7.3. The reaction was stirred for about 30 minutes

(25°C) and stopped by addition of 1 M lysine solution at 10 mM. Excess amounts of SATA and SATP were removed by dialysis against 10 mM potassium phosphate, 50 mM NaCl and 2 mM EDTA, pH 6.2. After removal of the protecting acetyl group with hydroxylamine, the number of thiol groups covalently linked to EPO was determined photometrically with dithiodipyridine according to the method described by Grasetti, D.R. and Murray, J. F. in J. Appl. Biochem. Biotechnol. 119, page 41-49 (1967).

The number of thiol groups covalently linked per EPO molecule is shown below.

Molar ratio EPO : SATA or SATP	Mol thiol groups / mol EPO
EPO : SATA = 1 : 3	1,5
EPO : SATA = 1 : 5	2.4
EPO : SATA = 1 : 6	3.2
EPO : SATP = 1 : 3	1.3
EPO : SATP = 1 : 4	2.5
EPO : SATP = 1 : 6	3.7

10

### EXAMPLE 3: Modification of activated EPO with methoxy-PEG-maleimide

#### A) Activation of EPO:

100 mg EPO produced according to Example 1 (190,000 IU/ mg as determined by the normocythaemic mouse assay) were activated with SATA (molar ratio: EPO/SATA = 1/5) according to Example 2. The resulting EPO ("activated EPO") carrying covalently linked blocked thiol groups was separated from by-products like N-hydroxy-succinimide or non-reacted SATA by dialysis as described in Example 1. A solution of 4.5 mg/ml activated EPO in 10 mM potassium phosphate, 50 mM NaCl, 2 mM EDTA, pH 6.2 was obtained.

#### 20 B) Pegylation of activated EPO:

380 mg methoxy-PEG-maleimide having the "most preferred" structure illustrated above (MW 30.000; Shearwater Polymers, Inc., Huntsville (Alabama, USA)) was dissolved in the above solution containing 95 mg activated EPO (4.5 mg/ml in 10 mM potassium phosphate, 50 mM NaCl, 2 mM EDTA, pH 6.2). The resulting molar ratio between activated EPO and methoxy-PEG-maleimide in the solution was 1 : 4. By addition of 1 M

25



aqueous hydroxylamine solution ad 30 mM, pH 6.2 to the above solution the covalently linked blocked thiol groups of activated EPO were de-blocked. The resulting activated EPO in the reaction mixture of the solution contained free thiol (-SH) groups. De-blocking of the thiol groups was followed immediately by the coupling reaction between  
5 the activated EPO now containing free thiol (-SH) groups and methoxy-PEG-maleimide for 90 minutes (stirring, 25°C). The coupling reaction was stopped by addition of 0.2 M aqueous cysteine solution ad 2 mM to the reaction mixture. After 30 minutes excess free thiol groups of the activated EPO which did not react with methoxy-PEG-maleimide were blocked by addition of a 0.5 M N-methylmaleimide solution in DMSO to reach a  
10 concentration of 5 mM. After 30 minutes the resulting reaction mixture now containing pegylated EPO species was dialyzed against 10 mM potassium phosphate, pH 7.5 for  $\geq 15$  hours.

#### C) Purification of pegylated EPO species:

For separation of the pegylated EPO species from the reaction mixture, the following  
15 purification process was performed: A 50 ml Q-Sepharose ff column was equilibrated with 10 mM potassium phosphate, pH 7.5. The reaction mixture obtained in step B) was loaded onto the column (flow rate: 3 column volumes (CV) per hour). In order to separate non-reacted methoxy-PEG-maleimide reagent, the column was washed with 5 CV's of 10 mM potassium phosphate, pH 7.5. Pegylated EPO species were separated by elution with an  
20 increasing salt gradient consisting of 5 CV's buffer A (10 mM potassium phosphate, pH 7.5) and 5 CV's buffer B (10 mM potassium phosphate, 500 mM NaCl, pH 7.5) with a flow rate of 3 CV per hour. Based on the NaCl gradient, the pegylated EPO species (tri-, bi- and mono-pegylated EPO species) were eluted first, followed by the non-pegylated EPO species. The fraction of the eluate containing the pegylated EPO species (tri-, di- and  
25 mono-pegylated EPO species) was pooled and filtered (sterile filtration with a 0.2  $\mu$ m filter).

Content and purity of tri-, di- and mono-pegylated EPO species were evaluated on Coomassie-stained SDS-PAA gels (Laemmli, Nature 227, 680-685 (1970)) while protein concentrations were measured at 280 nm according the Beer-Lambert law. The apparent  
30 molecular weights of the EPO species determined by SDS-PAA electrophoresis were about 68 kDa (mono-pegylated EPO species), about 98 kDa (di-pegylated EPO species), and about 128 kDa (tri-pegylated EPO species).

Further separation of the tri-, di and mono-pegylated EPO species can be achieved by chromatography, e.g. by size exclusion chromatography (Superdex, pg 200; Pharmacia).

The determination of in-vivo biological activity of the eluate containing tri- di- and mono-pegylated species was performed by the method described in Example 4.

**EXAMPLE 4: In-vivo activity of pegylated EPO determined  
by the normocythaemic mouse assay**

5

The normocythaemic mouse bioassay is known in the art (Pharm. Europa Spec. Issue Erythropoietin BRP Bio 1997(2)) and a method in the monography of erythropoietin of Ph. Eur. BRP. The samples are diluted with BSA-PBS. Normal healthy mice, 7-15 weeks old, are administered s.c. 0.2 ml of the EPO-fraction containing tri-, di- and mono-pegylated EPO as described in Example 2. Over a period of 4 days starting 72 hours after the administration, blood is drawn by puncture of the tail vein and diluted such that 1 µl of blood is present in 1 ml of an 0.15 µmol acridine orange staining solution. The staining time is 3 to 10 minutes. The reticulocyte counts are carried out microfluorometrically in a flow cytometer by analysis of the red fluorescence histogram. The reticulocyte counts are given in terms of absolute figures (per 30,000 blood cells analyzed). For the data presented, each group consisted of 5 mice per day, and the mice were bled only once.

10

15

20

Methoxy-PEG-maleimide coupled to EPO according to Example 3, unmodified EPO and buffer solution were administered to mice. The results are shown in Figure 3. The results show the superior activity and the prolonged half life of the pegylated EPO species indicated by the significantly increased amounts of reticulocytes and the shift of the reticulocytes count maximum using the same dose per mouse.


CLAIMS

1. A conjugate, said conjugate comprising an erythropoietin glycoprotein having at least one free amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the primary structure of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or by the rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to from one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the glycoprotein *via* a linker of the formula  $-\text{C}(\text{O})-\text{X}-\text{S}-\text{Y}-$  with the  $\text{C}(\text{O})$  of the linker forming an amide bond with one of said amino groups,

X is  $-(\text{CH}_2)_k-$  or  $-\text{CH}_2(\text{O}-\text{CH}_2-\text{CH}_2)_k-$ ,


k is from 1 to 10,

Y is




the average molecular weight of each poly(ethylene glycol) moiety is from about 20 kilodaltons to about 40 kilodaltons, and the molecular weight of the conjugate is from about 51 kilodaltons to about 175 kilodaltons.

2. The conjugate of claim 1, of the formula:




wherein X and Y are as defined in claim 1, m is from 450 to 900, n is from 1 to 3, R is lower alkyl and P is an erythropoietin glycoprotein less the amino group or amino groups which form an amide linkage with X.

3. The conjugate according to any preceding claim, of the formula



wherein P, R, X, m and n are as defined in claim 2.

4. The conjugate according to claims 1 or 2, of the formula



5 wherein P, R, X, m and n are as defined in claim 2.

5. The conjugate according to any preceding claim, wherein X is  $-(\text{CH}_2)_k-$ .
6. The conjugate according to claim 5, wherein k is from 1 to 4.
- 10 7. The conjugate according to any preceding claim, wherein X is  $-\text{CH}_2-$ .
8. The conjugate of any preceding claim, wherein m is an integer from 550 to 800.
- 15 9. The conjugate of any preceding claim, wherein m is an integer from 650 to 700.
10. The conjugate of any preceding claim, wherein n is 1.
11. The conjugate of any preceding claim, wherein R is methyl.
- 20 12. The conjugate according to any preceding claim, wherein the average molecular weight of each poly(ethylene glycol) moiety is from about 24 kilodaltons to about 35 kilodaltons.
- 25 13. The conjugate according to any preceding claim, wherein the average molecular weight of each poly(ethylene glycol) moiety is about 30 kilodaltons.

14. The conjugate according to any preceding claim, wherein the glycoprotein is covalently linked to one or two lower-alkoxy capped poly(ethylene glycol) moieties.
15. The conjugate according to any preceding claim, wherein the poly(ethylene glycol) moieties are capped by methoxy.
16. The conjugate of any preceding claim, wherein X is  $-\text{CH}_2-$ , m is an integer from 650 to 700, n is 1, R is methyl, and wherein the average molecular weight of each poly(ethylene glycol) moiety is about 30 kilodaltons.
17. The conjugate according to any preceding claim, wherein the erythropoietin glycoprotein is a human erythropoietin.
18. The conjugate according to any preceding claim, wherein the erythropoietin glycoprotein is expressed by endogenous gene activation.
19. The conjugate according to any preceding claim, wherein the erythropoietin glycoprotein has the sequence set out in Figure 1 (SEQ ID NO:1) or Figure 2 (SEQ ID NO:2).
20. The conjugate of claim 19, wherein the erythropoietin glycoprotein has the sequence set out in Figure 1 (SEQ ID NO:1).
21. The conjugate according to any of claims 1 to 16, wherein the glycoprotein has the sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites.
22. The conjugate according to any of claims 1 to 6, 8 and 10, wherein the glycoprotein has the sequence of human erythropoietin modified by a modification selected from the group consisting of:
- Asn<sup>30</sup>Thr<sup>32</sup>;  
Asn<sup>51</sup>Thr<sup>53</sup>;  
Asn<sup>57</sup>Thr<sup>59</sup>;  
Asn<sup>69</sup>;  
Asn<sup>69</sup>Thr<sup>71</sup>;  
Ser<sup>68</sup>Asn<sup>69</sup>Thr<sup>71</sup>;  
Val<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>;

Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup>;  
 Ser<sup>87</sup> Asn<sup>88</sup> Gly<sup>89</sup> Thr<sup>90</sup>;  
 Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> Thr<sup>92</sup>;  
 Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> Ala<sup>162</sup>;  
 5 Asn<sup>69</sup> Thr<sup>71</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup>;  
 Asn<sup>30</sup> Thr<sup>32</sup> Val<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup>;  
 Asn<sup>89</sup> Ile<sup>90</sup> Thr<sup>91</sup>;  
 Ser<sup>87</sup> Asn<sup>89</sup> Ile<sup>90</sup> Thr<sup>91</sup>;  
 Asn<sup>136</sup> Thr<sup>138</sup>;  
 10 Asn<sup>138</sup> Thr<sup>140</sup>;  
 Thr<sup>125</sup>; and  
 Pro<sup>124</sup> Thr<sup>125</sup>.

23. The conjugate according to any preceding claims, wherein the glycoprotein has a sequence comprising the sequence of human erythropoietin and a second sequence at the carboxy terminus of the human erythropoietin sequence, wherein the second sequence contains at least one glycosylation site.
24. The conjugate according to claim 23, wherein the second sequences comprises a sequence derived from the carboxy terminal sequence of human chorionic gonadotropin.
25. The conjugate of claim 24, wherein the glycoprotein has a sequence selected from the group consisting of:
- a) human erythropoietin having the amino acid sequence, Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln (SEQ ID NO:3), extending from the carboxy terminus;
  - b) the sequence in (a) modified by Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup>; and
  - c) the sequence in (a) modified by Asn<sup>30</sup> Thr<sup>32</sup> Val<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup>.
26. The conjugate according to any of claims 1 to 16, wherein the glycoprotein has the sequence of human erythropoietin modified by a rearrangement of at least one glycosylation site.
27. The conjugate according to claim 25, wherein the rearrangement comprises deletion of any of the N-linked carbohydrate sites in human erythropoietin and addition of

an N-linked carbohydrate site at position 88 of the sequence of human erythropoietin.

28. The conjugate of claim 14, wherein the glycoprotein has the sequence of human erythropoietin modified by a modification selected from the group consisting of:


Gln<sup>24</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO;  
 Gln<sup>38</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO; and  
 Gln<sup>83</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO.

29. A composition comprising conjugates, each of said conjugates comprising an erythropoietin glycoprotein having at least one free amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the primary structure of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or by the rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to from one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the glycoprotein *via* a linker of the formula -C(O)-X-S-Y- with the C(O) of the linker forming an amide bond with one of said amino groups,

X is -(CH<sub>2</sub>)<sub>k</sub>- or -CH<sub>2</sub>(O-CH<sub>2</sub>-CH<sub>2</sub>)<sub>k</sub>-,

k is from 1 to 10,

Y is



the average molecular weight of each poly(ethylene glycol) moiety is from about 20 kilodaltons to about 40 kilodaltons, and the molecular weight of the conjugate is from about 51 kilodaltons to about 175 kilodaltons; and the percentage of conjugates where n is 1 is at least ninety percent.

30. The composition comprising conjugates as defined in any of claims 1 to 27 wherein the percentage of conjugates where n is 1 is at least ninety percent.
- 5 31. The composition of according to claim 28 or 29 wherein the percentage of conjugates where n is 1 is at least ninety-two percent.
32. The composition of claim 30 wherein the percentage of conjugates where n is 1 is at least ninety-six percent.
- 10 33. The composition of claim 29 or 32 wherein the percentage of conjugates where n is 1 is from ninety percent to ninety-six percent.
34. A pharmaceutical composition comprising a conjugate or a composition according to any of claims 1 to 33 and a pharmaceutically acceptable excipient.
- 15 35. Use of a conjugate or a composition according to any of claims 1 to 33 for the preparation of medicaments for the treatment or prophylaxis of diseases correlated with anemia in chronic renal failure patients (CRF), AIDS and for the treatment of cancer patients undergoing chemotherapy.
- 20 36. A method for the prophylactic and/or therapeutic treatment of disorders involving anemia in chronic renal failure patients (CRF), AIDS and cancer patients undergoing chemotherapy comprising the step of administering to a patient a conjugate or composition as claimed in any one of claims 1 to 33.
- 25 37. A process for the preparation of a conjugate or a composition according to any of claims 1 to 33 which process comprises the covalent linking of thiol groups to an erythropoietin glycoprotein and coupling the resulting activated erythropoietin glycoprotein with a poly(ethylene glycol) (PEG) derivative.
- 30 38. Conjugates and compositions according to any of claims 1 to 33, whenever prepared by the process of claim 36.



39. Conjugates and compositions according to any of claims 1 to 33 for the treatment of diseases which are associated with anemia in chronic renal failure patients (CRF), AIDS and cancer patients undergoing chemotherapy.
- 5 40. The novel compounds, processes and methods as well as the use of such compounds substantially as described hereinbefore.

FIGURE 1

5

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg<sup>10</sup> Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys<sup>20</sup>

10

Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala<sup>30</sup> Glu His Cys Ser Leu Asn Glu Asn Ile Thr<sup>40</sup>

Val Pro Asp Thr Lys Val Asn Phe Tyr Ala<sup>50</sup> Trp Lys Arg Met Glu Val Gly Gln Gln Ala<sup>60</sup>

Val Glu Val Trp Gln Gly Leu Ala Leu Leu<sup>70</sup> Ser Glu Ala Val Leu Arg Gly Gln Ala Leu<sup>80</sup>

15

Leu Val Asn Ser Ser Gln Pro Trp Glu Pro<sup>90</sup> Leu Gln Leu His Val Asp Lys Ala Val Ser<sup>100</sup>

Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg<sup>110</sup> Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser<sup>120</sup>

20

Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu<sup>130</sup> Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys<sup>140</sup>

Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg<sup>150</sup> Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala<sup>160</sup>

Cys Arg Thr Gly Asp<sup>165</sup>


25

FIGURE 2

5 Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg<sup>10</sup> Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys<sup>20</sup>  
Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala<sup>30</sup> Glu His Cys Ser Leu Asn Glu Asn Ile Thr<sup>40</sup>  
10 Val Pro Asp Thr Lys Val Asn Phe Tyr Ala<sup>50</sup> Trp Lys Arg Met Glu Val Gly Gln Gln Ala<sup>60</sup>  
Val Glu Val Trp Gln Gly Leu Ala Leu Leu<sup>70</sup> Ser Glu Ala Val Leu Arg Gly Gln Ala Leu<sup>80</sup>  
15 Leu Val Asn Ser Ser Gln Pro Trp Glu Pro<sup>90</sup> Leu Gln Leu His Val Asp Lys Ala Val Ser<sup>100</sup>  
Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg<sup>110</sup> Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser<sup>120</sup>  
Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu<sup>130</sup> Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys<sup>140</sup>  
20 Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg<sup>150</sup> Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala<sup>160</sup>  
Cys Arg Thr Gly Asp Arg<sup>166</sup>

25

FIGURE 3



SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

## (i) APPLICANT:

(A) NAME: F.Hoffmann-La Roche AG  
 (B) STREET: 124 Grenzacherstrasse  
 (C) CITY: Basle  
 (E) COUNTRY: Switzerland  
 (F) POSTAL CODE (ZIP): CH-4070  
 (G) TELEPHONE: (61) 688 11 11  
 (H) TELEFAX: (61) 688 13 95  
 (I) TELEX: 962 292 hlr ch

15

(ii) TITLE OF INVENTION: Erythropoietin Conjugates

(iii) NUMBER OF SEQUENCES: 3

20

## (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: WORD  
 (D) SOFTWARE: PatentIn Release 2.0

25

&lt;170&gt; PatentIn Ver. 2.0

30

&lt;210&gt; 1

&lt;211&gt; 165

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

35

&lt;400&gt; 1

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu  
 1 5 10 15

Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His  
 20 25 30

Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe  
 35 40 45

Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp  
 50 55 60

Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu  
 65 70 75 80

Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp  
 85 90 95

Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu  
 100 105 110

Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala  
 115 120 125

Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val  
 130 135 140

Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala  
 145 150 155 160

Cys Arg Thr Gly Asp  
165

5 <210> 2  
<211> 166  
<212> PRT  
<213> Homo sapiens

10 <400> 2  
Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu  
1 5 10 15  
Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His  
15 20 25 30  
Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe  
35 40 45  
20 Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp  
50 55 60  
Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu  
65 70 75 80  
25 Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp  
85 90 95  
30 Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu  
100 105 110  
Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala  
115 120 125  
35 Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val  
130 135 140  
Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala  
145 150 155 160  
40 Cys Arg Thr Gly Asp Arg  
165

45 <210> 3  
<211> 28  
<212> PRT  
<213> Homo sapiens

50 <400> 3  
Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg  
1 5 10 15  
Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln  
55 20 25

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number  
**WO 01/02017 A3**

- (51) International Patent Classification<sup>7</sup>: C07K 14/505. A61K 47/48
- (21) International Application Number: PCT/EP00/06009
- (22) International Filing Date: 28 June 2000 (28.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/142,243 2 July 1999 (02.07.1999) US  
60/147,452 5 August 1999 (05.08.1999) US  
60/151,454 30 August 1999 (30.08.1999) US
- (71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH];  
124 Grenzacherstrasse, CH-4070 Basle (CH).
- (72) Inventors: BURG, Josef; An der Bärenmühle 1, D-82362  
Weilheim (DE). HILGER, Bernd; 21 Am Katzenbuckel,  
D-82377 Penzberg (DE). JOSEL, Hans-Peter; Prälaten-  
weg 7, D-82362 Weilheim (DE).
- (74) Agent: WITTE, Hubert; Grenzacherstrasse 124,  
CH-4070 Basle (CH).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,  
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,  
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,  
VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
9 August 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/02017 A3

(54) Title: ERYTHROPOIETIN CONJUGATES WITH POLYETHYLENGLYCOL

(57) Abstract: Erythropoietin glycoprotein conjugates are disclosed, said conjugates comprise an erythropoietin glycoprotein having at least one free amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the primary structure of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or by the rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to form one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the glycoprotein via a linker of the formula -C(O)-X-S-Y- with the C(O) of the linker forming an amide bond with one of said amino groups, wherein X and Y are as defined in the description and claims, the average molecular weight of each poly(ethylene glycol) moiety is from about 20 kilodaltons to about 40 kilodaltons, and the molecular weight of the conjugate is from about 51 kilodaltons to about 175 kilodaltons.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/06009

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07K14/505 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 28024 A (ENZON INC.) 8 December 1994 (1994-12-08) the whole document	1-39
A	EP 0 605 963 A (ORTHO PHARMACEUTICAL CORPORATION) 13 July 1994 (1994-07-13) the whole document	1-39
A	EP 0 640 619 A (AMGEN) 1 March 1995 (1995-03-01) cited in the application the whole document	1-39

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

19 February 2001

Date of mailing of the international search report

27/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Masturzo, P



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 40

Claim 40 was not searched due to its absolute lack of clarity. Claim 38 was searched as if it was dependent on claim 37 in place of 36 as written in the text.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/06009

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9428024 A	08-12-1994	AU 7097094 A	20-12-1994
EP 605963 A	13-07-1994	AU 5238393 A	23-06-1994
		FI 935485 A	10-06-1994
		JP 7196925 A	01-08-1995
		KR 254650 B	01-05-2000
		KR 257643 B	15-05-2000
		NO 934477 A	10-06-1994
		NZ 250375 A	26-07-1995
		CA 2110543 A	10-06-1994
		ZA 9309214 A	08-06-1995
EP 640619 A	01-03-1995	AT 155796 T	15-08-1997
		AU 677097 B	10-04-1997
		AU 7632794 A	14-03-1995
		CN 1105030 A, B	12-07-1995
		CZ 9500917 A	13-03-1996
		DE 69404401 D	04-09-1997
		DE 69404401 T	19-02-1998
		DK 640619 T	02-02-1998
		ES 2105442 T	16-10-1997
		FI 951792 A	18-05-1995
		GR 3024815 T	30-01-1998
		HK 1001589 A	26-06-1998
		HU 72849 A	28-05-1996
		JP 11155584 A	15-06-1999
		JP 2938572 B	23-08-1999
		JP 8506023 T	02-07-1996
		LV 10972 A	20-12-1995
		LV 10972 B	20-10-1996
		NO 951445 A	16-06-1995
		NZ 273134 A	24-11-1997
		SI 640619 T	28-02-1998
		SK 50295 A	09-08-1995
		WO 9505465 A	23-02-1995
		ZA 9406122 A	20-03-1995